TY - JOUR
AU - Cozzolino, Mario
AB - Secondary hyperparathyroidism (SHPT) is a major complication of chronic kidney disease (CKD), responsible for skeletal and vascular damage with increased risk of bone fractures, cardiovascular events, and mortality. However, the optimal serum parathormone (PTH) levels for improving clinical outcomes remain uncertain. Treatment of SHPT is based on nutritional therapy, phosphate binders, vitamin D, and calcimimetics, but none of these interventions has ever been tested against pla- cebo in randomized controlled trials. Treatment of SHPT in the elderly should consider the many peculiarities of aging in terms of physiopathology, quality of life, symptoms, subjective perception of disease, drug load, and the modifying effect of treatment on disease-related outcomes. Unfortunately, peculiarities of SHPT among elderly CKD patients are mainly unexplored. The present review aims to provide a reasonable merging of evidence regarding the management of SHPT in CKD, with more actual concepts on how to care for older patients. mortality [3–5]. However, the best targets of PTH, to be 1 Introduction achieved and maintained at the different stages of CKD in order to improve clinically relevant outcomes, are still based Secondary hyperparathyroidism (SHPT) represents a major on observational data rather than on dedicated randomized complication of mineral disorder in chronic kidney 
TI - Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly
JF - Drugs & Aging
DO - 10.1007/s40266-019-00696-3
DA - 2019-07-15
UR - https://www.deepdyve.com/lp/springer-journals/management-of-secondary-hyperparathyroidism-in-chronic-kidney-disease-XTMQY4af8P
SP - 1
EP - 11
VL - OnlineFirst
IS - 
DP - DeepDyve
ER -